Patents by Inventor Sakari Kauppinen

Sakari Kauppinen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220213477
    Abstract: Methods of treating Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), comprising administering an inhibitory nucleic acid that targets miR-128.
    Type: Application
    Filed: December 21, 2021
    Publication date: July 7, 2022
    Inventors: Anders M. Naar, Sakari Kauppinen, Andreas Petri
  • Patent number: 11236336
    Abstract: Methods of treating Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), comprising administering an inhibitory nucleic acid that targets miR-128.
    Type: Grant
    Filed: March 24, 2020
    Date of Patent: February 1, 2022
    Assignees: The General Hospital Corporation, Aalborg University
    Inventors: Anders M. Naar, Sakari Kauppinen, Andreas Petri
  • Publication number: 20210071181
    Abstract: The invention provides pharmaceutical compositions comprising short single stranded oligonucleotides, of length of between 8 and 17 nucleobases which are complementary to human microRNAs. The short oligonucleotides are particularly effective at alleviating miRNA repression in vivo. It is found that the incorporation of high affinity nucleotide analogues into the oligonucleotides results in highly effective anti-microRNA molecules which appear to function via the formation of almost irreversible duplexes with the mIRNA target, rather than RNA cleavage based mechanisms, such as mechanisms associated with RNaseH or RISC.
    Type: Application
    Filed: October 1, 2020
    Publication date: March 11, 2021
    Inventors: Joacim ELMEN, Phil KEARNEY, Sakari KAUPPINEN
  • Publication number: 20210017521
    Abstract: The present disclosure provides compositions and methods that inhibit the activity of microRNAs, for example miR-22.
    Type: Application
    Filed: March 14, 2019
    Publication date: January 21, 2021
    Inventors: Pier Paolo PANDOLFI, Riccardo PANELLA, Sakari KAUPPINEN, Andreas PETRI
  • Publication number: 20200362342
    Abstract: Methods of treating Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), comprising administering an inhibitory nucleic acid that targets miR-128.
    Type: Application
    Filed: March 24, 2020
    Publication date: November 19, 2020
    Inventors: Anders M. Naar, Sakari Kauppinen, Andreas Petri
  • Patent number: 10787665
    Abstract: The present disclosure relates to antisense oligomers targeting the long non-coding RNA HOXB-AS3 and methods of treating acute myeloid leukemia.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: September 29, 2020
    Assignees: Ohio State Innovation Foundation, Aalborg University
    Inventors: Ramiro Garzon, Adrienne Dorrance, Dimitrios Papaioannou, Robert Lee, Sakari Kauppinen, Andreas Petri, Charlotte AlbÆk Thrue
  • Patent number: 10626395
    Abstract: Methods of treating Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), comprising administering an inhibitory nucleic acid that targets miR-128.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: April 21, 2020
    Assignees: The General Hospital Corporation, Aalborg University
    Inventors: Anders M. Naar, Sakari Kauppinen, Andreas Petri
  • Publication number: 20200017856
    Abstract: Methods for treating cancer, e.g., cancer of epithelial origin, by specifically targeting human satellite II (HSATII) using sequence specific agents such as oligonucleotides.
    Type: Application
    Filed: April 24, 2019
    Publication date: January 16, 2020
    Inventors: David T. Ting, Daniel A. Haber, Shyamala Maheswaran, Francesca Bersani, Anders M. Naar, Mihir Shivadatta Rajurkar, Sakari Kauppinen, Andreas Petri
  • Patent number: 10450564
    Abstract: The present invention relates to very short heavily modified oligonucleotides which target and inhibit microRNAs in vivo, and their use in medicaments and pharmaceutical compositions.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: October 22, 2019
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Susanna Obad, Sakari Kauppinen, Joacim Elmen, Morten Lindow, Markus Heidenblad
  • Publication number: 20190270993
    Abstract: Methods of treating Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), comprising administering an inhibitory nucleic acid that targets miR-128.
    Type: Application
    Filed: September 18, 2017
    Publication date: September 5, 2019
    Inventors: Anders M. Naar, Sakari Kauppinen, Andreas Petri
  • Publication number: 20190256848
    Abstract: The present disclosure relates to antisense oligomers targeting the long non-coding RNA HOXB-AS3 and methods of treating acute myeloid leukemia.
    Type: Application
    Filed: November 3, 2017
    Publication date: August 22, 2019
    Inventors: Ramiro GARZON, Adrienne DORRANCE, Dimitrios PAPAIOANNOU, Robert LEE, Sakari KAUPPINEN, Andreas PETRI, Charlotte ALBÆK THRUE
  • Patent number: 10301624
    Abstract: Methods for treating cancer, e.g., cancer of epithelial origin, by specifically targeting human satellite II (HSATII) using sequence specific agents such as oligonucleotides. As shown herein, the hetero chromatic HSATII satellite repeat is silenced in normal cells, but massively over expressed in epithelial cancers and in cancer cell lines when grown as xenografts or in 3D culture. Induction of HSATII RNA, either in xenografts or using in vitro reconstitution models, suggests the appearance of complementary DNA intermediates.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: May 28, 2019
    Assignees: The General Hospital Corporation, Aalborg University
    Inventors: David T. Ting, Daniel A. Haber, Shyamala Maheswaran, Francesca Bersani, Anders M. Naar, Mihir Shivadatta Rajurkar, Sakari Kauppinen, Andreas Petri
  • Publication number: 20190071672
    Abstract: The invention provides pharmaceutical compositions comprising short single stranded oligonucleotides, of length of between 8 and 17 nucleobases which are complementary to human microRNAs. The short oligonucleotides are particularly effective at alleviating miRNA repression in vivo. It is found that the incorporation of high affinity nucleotide analogues into the oligonucleotides results in highly effective anti-microRNA molecules which appear to function via the formation of almost irreversible duplexes with the miRNA target, rather than RNA cleavage based mechanisms, such as mechanisms associated with RNaseH or RISC.
    Type: Application
    Filed: September 10, 2018
    Publication date: March 7, 2019
    Inventors: Joacim Elmen, Phil Kearney, Sakari Kauppinen
  • Publication number: 20180201928
    Abstract: The present invention relates to very short heavily modified oligonucleotides which target and inhibit microRNAs in vivo, and their use in medicaments and pharmaceutical compositions.
    Type: Application
    Filed: September 15, 2017
    Publication date: July 19, 2018
    Inventors: Susanna Obad, Sakari Kauppinen, Joacim Elmen, Morten Lindow, Markus Heidenblad
  • Publication number: 20180195062
    Abstract: The invention provides pharmaceutical compositions comprising short single stranded oligonucleotides, of length of between 8 and 17 nucleobases which are complementary to human microRNAs. The short oligonucleotides are particularly effective at alleviating miRNA repression in vivo. It is found that the incorporation of high affinity nucleotide analogues into the oligonucleotides results in highly effective anti-microRNA molecules which appear to function via the formation of almost irreversible duplexes with the miRNA target, rather than RNA cleavage based mechanisms, such as mechanisms associated with RNaseH or RISC.
    Type: Application
    Filed: September 13, 2017
    Publication date: July 12, 2018
    Inventors: Joacim Elmen, Phil Kearney, Sakari Kauppinen
  • Patent number: 9790493
    Abstract: The present invention relates to very short heavily modified oligonucleotides which target and inhibit microRNAs in vivo, and their use in medicaments and pharmaceutical compositions.
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: October 17, 2017
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Susanna Obad, Sakari Kauppinen, Joacim Elmen, Morten Lindow, Markus Heidenblad
  • Publication number: 20160355804
    Abstract: There is provided nucleic acids (mir-138Antimirs) for use in treating or preventing bone loss in a patient. Also there is provided a method for reducing the levels of endogenous mir-138 in a cell.
    Type: Application
    Filed: January 7, 2016
    Publication date: December 8, 2016
    Inventors: Moustapha KASSEM, Basem ABDALLAH, Hanna TAIPALEENMAEKI, Sakari KAUPPINEN, Tilde ESKILDSEN, Jan STENVANG
  • Patent number: 9464106
    Abstract: The invention features improved nucleic acids and methods for expression profiling of mRNAs, identifying and profiling of particular mRNA splice variants, and detecting mutations, deletions, or duplications of particular exons or other splice variants, e.g., alterations associated with a disease such as cancer, in a nucleic acid sample, e.g., a biological sample or a patient sample.
    Type: Grant
    Filed: November 14, 2011
    Date of Patent: October 11, 2016
    Assignee: Exiqon A/S
    Inventors: Sakari Kauppinen, Carsten Alsbo, Peter S. Nielsen, Daniel C. Jeffares, Tobias Mourier, Søren Mørk, Peter Arctander, Niels Tommerup, Niels Tolstrup, Henrik Vissing, Søren Morgenthaler Echwald
  • Publication number: 20160060627
    Abstract: The invention provides pharmaceutical compositions comprising short single stranded oligonucleotides, of length of between 8 and 17 nucleobases which are complementary to human microRNAs. The short oligonucleotides are particularly effective at alleviating miRNA repression in vivo. It is found that the incorporation of high affinity nucleotide analogues into the oligonucleotides results in highly effective anti-microRNA molecules which appear to function via the formation of almost irreversible duplexes with the miRNA target, rather than RNA cleavage based mechanisms, such as mechanisms associated with RNaseH or RISC.
    Type: Application
    Filed: September 3, 2015
    Publication date: March 3, 2016
    Inventors: Joacim ELMEN, Phil Kearney, Sakari Kauppinen
  • Publication number: 20150299699
    Abstract: The present invention relates to very short heavily modified oligonucleotides which target and inhibit microRNAs in vivo, and their use in medicaments and pharmaceutical compositions.
    Type: Application
    Filed: October 29, 2014
    Publication date: October 22, 2015
    Inventors: Susanna OBAD, Sakari Kauppinen, Joacim Elmén, Morten Lindow, Markus Heidenblad